Spanish Decision Tool for Ovarian Cancer Maintenance Therapy
for
Ovarian Cancer
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center
Sex: All
Age: 18+
Code: NCT06036810
Recruiting
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
for
Low Grade Serous Ovarian Cancer
Location: New Haven CT, New York NY, Montreal, Philadelphia PA,
Sponsor: Verastem, Inc.
Sex: Female
Age: 18+
Code: NCT06072781
Phase3, Recruiting
A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers
A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
for
Ovarian Cancer, Solid Tumor
Location: Boston MA, New Haven CT, New York NY, Fairfax VA,
Sponsor: OnCusp Therapeutics, Inc.
Sex: All
Age: 18+
Code: NCT06234423
Phase1, Recruiting
A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib
for
Endometrioid Cancer, Mucinous Ovarian Cancer,
Location: Orlando FL, New Orleans LA, Oklahoma City OK,
Sponsor: University of Oklahoma
Sex: Female
Age: 18 - 70+
Code: NCT05512208
Phase2, Recruiting
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
for
Ovarian Cancer, Fallopian Tube, Primary Peritoneal Cancer
Location: Richmond VA, Pittsburgh PA, Columbus OH, Birmingham AL,
Sponsor: University of Alabama at Birmingham
Sex: Female
Age: 18+
Code: NCT04606914
Phase2, Recruiting
HIPEC After Initial CRS in Patients Who Have Received NACT
for
Ovarian Cancer, Fallopian Tube Cancer,
Location: New Hyde Park NY
Sponsor: Northwell Health
Sex: Female
Age: 18 - 70+
Code: NCT03540017
Phase1, Recruiting
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Location: New York NY, Rochester NY, Atlanta GA, Denver CO,
Sponsor: Nammi Therapeutics Inc
Sex: All
Age: 18+
Code: NCT06582017
Phase1, Recruiting
Combination Therapy for Recurrent Ovarian Cancer
for
Recurrent Ovarian Cancer
Location: Louisville KY
Sponsor: Sham Sunder Kakar
Sex: Female
Age: 18+
Code: NCT05610735
Phase1, Phase2, Recruiting
Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer
for
Ovarian Cancer, Stage III Ovarian Cancer,
Location: Toronto
Sponsor: Sunnybrook Health Sciences Centre
Sex: Female
Age: 18+
Code: NCT05961124
Phase2, Recruiting
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
for
Pancreatic Cancer, Renal Cell Cancer, Breast Cancer, Melanoma,
Location: Bethesda MD
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18 - 70+
Code: NCT02830724
Phase1, Phase2, Recruiting
Gonadal Dysgenesis Tissue Cryopreservation for Fertility Preservation
for
Ovarian Cancer
Location: Aurora CO
Sponsor: University of Colorado, Denver
Sex: All
Age: 0 - 30
Code: NCT06518746
Recruiting
Whole Body Hyperthermia Combined With Chemotherapy in Treating Patients With Metastatic Breast, Ovarian, Endometrial, or Cervical Cancer
for
Breast Cancer, Cervical Cancer, Endometrial Cancer,
Location: Houston TX
Sponsor: The University of Texas Health Science Center, Houston
Sex: Female
Age: 18+
Code: NCT00003135
Phase2, Recruiting
DOD Long-Term Survivors of Ovarian Cancer
for
Ovarian Cancer
Location: Boston MA
Sponsor: Massachusetts General Hospital
Sex: Female
Age: 18 - 70+
Code: NCT02321735
Recruiting
A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors
for
Solid Tumor, Breast Cancer, Pancreatic Cancer, Ovarian Cancer,
Location: Huntersville NC, Detroit MI, Houston TX,
Sponsor: Qurgen Inc.
Sex: All
Age: 18+
Code: NCT05989724
Phase1, Recruiting
Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemotherapy
for
Ovarian Cancer, Ovarian Carcinoma, Ovarian Cancer Stage IV,